Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443074 | 1.00 | HDAC11 (0.42) | HDAC11EGLN1LIPEKDM4EALDH1A1 | |
| SCHEMBL29443012 | 0.84 | HDAC11 (0.38) | HDAC11LIPEMAPTMEN1KMT2A | |
| SCHEMBL21490366 | 0.84 | HDAC11 (0.38) | HDAC11LIPEMAPTMEN1KMT2A | |
| SCHEMBL29443020 | 0.82 | ROCK2 (0.44) | LIPEALDH1A1 | |
| SCHEMBL21490362 | 0.82 | ROCK2 (0.44) | LIPEALDH1A1 | |
| SCHEMBL29348863 | 0.80 | HRH3 (0.43) | EGLN1LIPEITGB3ITGA2BHRH3 | |
| SCHEMBL22396051 | 0.77 | HRH3 (0.43) | EGLN1LIPEITGB3ITGA2BHRH3 | |
| SCHEMBL2476740 | 0.77 | HRH3 (0.56) | EGLN1LIPEMEN1KMT2AITGB3 | |
| SCHEMBL23529088 | 0.76 | EGLN1 (0.56) | EGLN1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL24742790 | 0.76 | EGLN1 (0.42) | EGLN1LIPEMEN1KMT2AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689639-B | Spirolactams as ROCK inhibitors | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3481817-B1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696674-B2 | Spirolactams as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | HDAC11 670/4885EGLN1 3972/4885LIPE 4528/4885 |
| US-20190322664-A1 | SPIROLACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | HDAC11 670/4885EGLN1 3972/4885LIPE 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.